Our Innovation Journey

At Glenmark, we explore the unparalleled possibilities of science and innovation to create breakthrough therapies for the global patient population. Our sustained investment in research and development helps us identify and advance promising treatments that benefit millions of patients globally. We are home to some of the best global scientific talent that continuously challenges treatment paradigms and builds on the success of established franchises. At present, our portfolio of differentiated medicines in respiratory, dermatology and oncology is acclaimed as breakthrough solutions for a wide range of diseases.

Our innovation footprint

2molecules

2 molecules

in Glenmark Pharmaceuticals’ speciality/innovative pipeline

5molecules

5 molecules

in Ichnos’ innovative biologics pipeline

inventions till date

1400+

inventions till date

patents

1300

patents granted for innovations in
NCE, Formulations, API and Design

licensingdeals

~ USD 300 Mn

worth of out-licensing deals signed

Reference : Glenmark Annual Report 2022 – 2023

Enriching lives globally through our products

First company to launch oral drug Favipiravir (FabiFlu®), in India for the treatment of mild to moderate COVID-19 cases which has helped in the treatment of > 5 Mn patients till date.

Ryaltris™ (olopatadine hydrochloride and mometasone furoate monohydrate), an anti-allergy nasal spray is being marketed globally as a treatment option for seasonal and perennial allergic rhinitis in adults and children over 12 years of age.

First company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India under two brand names Remo MV and Remozen MV.

fabiflu
ryaltris
remo

Out-licensing deals over the years

Glenmark’s 100% subsidiary Ichnos Sciences and Almirall enter into a licensing agreement for first-in-class iL-1RAP antagonist monoclonal antibody ISB 880. Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.

2021
GLENMARK’S SUBSIDIARY ICHNOS SCIENCES ENTERS INTO A LICENSING AGREEMENT

Glenmark out-licenses mPGES-1 inhibitor to Forest Labs for USD 15 Mn (upfront payment)

2012
OUT-LICENSES ANOTHER NOVEL MOLECULE

Glenmark out-licenses GBR 500 to Sanofi-Aventis for USD 50 Mn (upfront payment) and USD 5 Mn (milestone payment) in 2014

2011
OUT-LICENSES FIRST NEW BIOLOGIC ENTITY

Glenmark out-licenses GRC 15300, a first-in-class TRPV3 antagonist to Sanofi-Aventis for USD 25 Mn (upfront payment)

2010
OUT-LICENSES FIRST-IN-CLASS MOLECULE

Glenmark out-licenses TRPV1 antagonist molecules to Eli Lilly for USD 45 Mn (upfront fee)

2007
OUT-LICENSES 1ST PORTFOLIO

Glenmark out-licenses Melogliptin to Merck KGaA for USD 31 Mn (total payment)

2006
OUT-LICENSES 3RD MOLECULE

Glenmark out-licenses Oglemilast to Teijin Pharma, Japan for USD 6 Mn (upfront payment)

2005
OUT-LICENSES 2ND MOLECULE

Glenmark out-licenses GRC 3886 to Forest Laboratories for USD 35 Mn (upfront and milestone payments)

2004
FIRST MOLECULE OUT-LICENSED

In the news

News

Quality Glenmark Icon

R&D PIPELINE

Global Presence Icon

R&D CENTRES

Cutting edge innovation to find a better tomorrow